Saira Mushtaq, MD
Psychiatry · Houston, TXNPI 1245524495
Payments from drug & device makers
Across 50 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$269
- Takeda Pharmaceuticals U.S.A., Inc.$163
- Johnson & Johnson$102
- Otsuka America Pharmaceutical, Inc.$78
- Sunovion Pharmaceuticals Inc.$72
- Alkermes, Inc.$61
- plus $80 from 2 others
What the payments were for
- Food & beverage$81999%
- Education$51%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $163 |
| Johnson & Johnson | 5 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $72 |
| Alkermes, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Neuronetics, Inc. | 1 | $23 |
How this compares
$824 in reported general payments places this provider in the 65th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quillivant XrMethylphenidate Hcl | 12 | $9,650 |
| Aripiprazole | 25 | $892 |
| Buspirone Hcl | 50 | $472 |
| Quetiapine Fumarate | 92 | $450 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $446 |
| Fluoxetine Hcl | 71 | $384 |
| Bupropion Hcl SrBupropion Hcl | 30 | $361 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $332 |
| Sertraline Hcl | 69 | $322 |
| Methylphenidate Hcl | 16 | $273 |
| Duloxetine Hcl | 22 | $237 |
| Trazodone Hcl | 50 | $214 |
| Escitalopram Oxalate | 21 | $185 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $171 |
| Benztropine Mesylate | 16 | $145 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.